News
-
-
-
-
-
-
-
PRESS RELEASE
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory UC Patients and Strengthening the Phase 3 Maintenance Safety Database
Abivax reports positive ABTECT Maintenance Part 2 results for obefazimod in refractory UC patients, demonstrating meaningful clinical benefit and strengthening safety database -
-
PRESS RELEASE
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
DBV Technologies updates on BLA submission for VIASKIN Peanut Patch in children aged 4-7 years, optimizing the review process with FDA for a complete and efficient review -